

June 15, 2023

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

BSE Script Code: 531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

NSE Symbol: FDC

Sub:- US - FDA Inspection at Company's manufacturing facility located at Waluj, Aurangabad- Receipt of EIR with No Action Indicated ("NAI")

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

This is further to the intimation given by the company dated February 13, 2023, the U.S. Food and Drug Administration (FDA) had conducted an inspection at company's manufacturing facility located at B-8 MIDC Industrial Area, Waluj District, Aurangabad, Maharashtra State, from 6th February 2023 to 12th February 2023. FDA has determined that the inspection classification of this facility is "no action indicated" ("NAI"). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

FDA has concluded that this inspection is "closed" and a copy of the narrative portion of the Establishment Inspection Report (EIR) has been issued.

Kindly take the above on record.

Yours truly,

For FDC LIMITED

Varsharani Katre

Company Secretary & Compliance Officer

Membership No.: FCS-8948